Addison’s Disease Market Research Report- Forecast till 2030

Addison’s Disease Market Research Report by Diagnosis (Laboratory Testing and Imaging Tests), Treatment (Oral Corticosteroid and Corticosteroid Injections), End User (Hospitals and Clinics, Diagnostic Laboratories, and Others)-Forecast till 2030

ID: MRFR/Pharma/5165-HCR | February 2023 | Region: Global | 90 Pages         

Addison’s Disease Market Speak to Analyst Request a Free Sample

Addison’s Disease Market

Addison's Disease Market size is expected to grow significantly of USD 587.45 million in 2030 and is projected to grow at a CAGR of 10.70% over the forecast period

Segmentation
By Diagnosis Laboratory Testing and Imaging Tests
Treatment Oral Corticosteroid and Corticosteroid Injections
End User Hospitals and Clinics Diagnostic Laboratories and Others
Key Players
Companies Profiled   Pfizer Inc    Boehringer Ingelheim International GmbH    Shire    Tocris Bioscience    GlaxoSmithKline plc    Merck KGaA    Lupin Pharmaceuticals    Abbott    Amgen Limited & Amgen Ireland Limited    Bayer AG
Drivers
Market Driving Forces   rowing prevalence of Addison’s disease    increasing awareness of the disease    rising healthcare expenditure
Request a Free Sample

Addison’s Disease Market Overview:


Addison's Syndrome Over the forecast period, the market is predicted to increase considerably. The market is expected to be worth USD 587.45 million in 2030, and it is expected to increase at a CAGR of 10.70% over the forecast period. Addison's disease is a condition in which the body generates insufficient levels of certain hormones made by the adrenal glands. The adrenal glands generate too little cortisol and typically insufficient quantities of aldosterone in people with Addison's disease.


Adrenal insufficiency is another name for it. Addison's disease may afflict people of all ages and impact both men and women. The market is predicted to rise due to reasons such as the rising prevalence of Addison's disease, increased awareness of the condition, and rising healthcare spending. Lack of knowledge and difficulty to detect the condition in its early stages, on the other hand, may limit market growth throughout the projection period.Segmentation


The Global Addison’s Disease Market has been segmented into diagnosis, treatment and end user.

The market, on the basis of diagnosis, has been segmented into laboratory tests and imaging tests. Laboratory tests have been further segmented into blood tests, ACTH stimulation tests, insulin-induced hypoglycemia test, and other tests. Blood tests are expected to hold the largest market share owing to their high effectiveness to diagnose the disease and preference among the physicians. ACTH stimulation test is expected to be the fastest growing market due to the low cost of the diagnosis method. Imaging tests have been segmented into chest radiography and CT scan.

The market, by treatment, has been segmented into oral corticosteroids and corticosteroids injections.

The market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, and other end users.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The Addison’s disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key Players



  • Pfizer Inc

  • Boehringer Ingelheim International GmbH

  • Shire

  • Tocris Bioscience

  • GlaxoSmithKline plc

  • Merck KGaA

  • Lupin Pharmaceuticals, Inc

  • Abbott

  • Amgen Limited & Amgen Ireland Limited

  • Bayer AG

  • Biogen

  • Eli Lilly and Company

  • Novartis AG

  • Diurnal

  • Switzer Life science Pvt. Ltd


Regional Market Summary


Global Addison’s Disease Market Share (%), by Region, 2017


Global Addison’s Disease Market Share (%), by Region, 2017 Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports


Geographically, the Americas is anticipated to dominate the global Addison's disease market owing to a well-developed healthcare sector and the rising prevalence of the disease. According to a report published by the Centers Medicare and Medicaid Services in April 2018, National Healthcare Expenditure grew by 4.3% to USD 3.3 trillion in 2016 from the previous year.


Europe is expected to hold the second largest position in the global market. The market growth in this region is attributed to the increasing number of Addison’s disease cases and the developed healthcare infrastructure. According to the World Health Organization, Germany spent USD 5182 per capita on healthcare.


The Addison’s disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the increasing prevalence of Addison’s disease and growing awareness of the same. According to the World Bank Group, India spent 3.89% of its GDP on health in 2015.


The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.Recent Development


Lupin Ltd (Lupin) is a pharmaceutical company that produces and markets generic and branded pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Cardiovascular, diabetes etc are all part of the company's product range. Oral, ophthalmic, dermatological, and inhalation product research are key priorities for the organization. The company's operations are reported under a single segment, Pharmaceuticals. Formulations, active pharmaceutical ingredients (APIs), generic formulations, and biotechnology products are all part of Lupin's business.


In August 2015, Amgen, a biotechnology corporation located in the United States, launched its significantly enlarged production plant in Dun Laoghaire, Ireland. The $300 million expansion expanded manufacturing facilities to the existing factory, enhancing its capabilities and positioning it as a major hub for Amgen's global operations. The move was part of Amgen's long-term plan to manufacture all of its pharmaceuticals at the Dun Laoghaire facility, ensuring a steady supply of Amgen's medicines for severely sick patients across the world.


Global Addison’s Disease Market, by Diagnosis




  • Laboratory Tests

    • Blood Tests

    • ACTH Stimulation Tests

    • Insulin-Induced Hypoglycemia Test

    • Other Tests






  • Imaging Tests

    • Chest Radiography

    • CT Scan




Global Addison’s Disease Market, by Treatment



  • Oral Corticosteroid

  • Corticosteroid Injections


Global Addison’s Disease Market, by End User



  • Hospitals and Clinics

  • Diagnostic Laboratories

  • Other End Users


Global Addison’s Disease Market, by Region




  • Americas


    • North America

      • US

      • Canada



    • South America






  • Europe


    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe






  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific






  • Middle East & Africa

    • Middle East

    • Africa




Global Addison’s Disease Market, by Key Players



  • Pfizer Inc.

  • Boehringer Ingelheim International GmbH

  • Shire

  • Tocris Bioscience

  • GlaxoSmithKline Plc

  • Merck KGaA

  • Lupin Pharmaceuticals, Inc.

  • Abbott

  • Amgen Limited & Amgen Ireland Limited



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 587.45 million
  CAGR   2020-2030:10.70%
  Base Year   2020
  Forecast Period   2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment And End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors    Pfizer Inc., Boehringer Ingelheim International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline plc, Merck KGaA, Lupin Pharmaceuticals, Inc., Abbott, Amgen Limited & Amgen Ireland Limited, Bayer AG, Biogen, Eli Lilly and Company, Novartis AG, Diurnal, Switzer Life science Pvt. Ltd
  Key Market Opportunities   R&D Activities
  Key Market Drivers

  • Growing prevalence of Addison’s disease
  • Increasing awareness of the disease
  • Rising healthcare expenditure


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The Addison’s disease market is projected to grow at a 10.70% CAGR between 2020-2030.

    North America is projected to command the largest share in the Addison’s disease market.

    Oral corticosteroids segment will dominate the Addison’s disease market.

    Rising healthcare expenditure and growing awareness about the disease is boosting market growth.

    Inability to diagnose Addison’s disease may limit market growth.